Date:5/9/2011

sales cycle and bulk purchases of consumables, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex' foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex' Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2011 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.Contacts:

Harriss T. Currie

Matthew ScaloVice President, Finance and Chief Financial Officer

Sr. Director of Investor Relations512-219-8020

512-219-8020hcurrie@luminexcorp.com

mscalo@luminexcorp.com LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)March 31,December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

$
94,561$
89,487Restricted cash

1,0031,002Short-term investments

27,05228,404Accounts receivable, net
'/>"/>

SOURCE Luminex Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011
2. Luminex Corporation Wins Prestigious Medical Design Excellence Award
3. Luminex Corporation to Present at Cowen and Companys 31st Annual Health Care Conference
4. Luminex Corporation Ranked One of the 25 Fastest-Growing Technology Companies in America by Forbes for Third Consecutive Year
5. Luminex and Partners HealthCare Announce Collaboration Agreement
6. Luminex Corporation Reports Fourth Quarter and Full Year 2010 Results
7. Luminex Corporation Fourth Quarter and Full Year 2010 Earnings Release Scheduled for February 7, 2011
8. Luminex Corporation to Present at JP Morgan Healthcare Conference
9. Luminex and One Lambda Renew Long-Term Strategic Partnership
10. Luminex Corporation Board of Directors Authorizes Share Repurchase Plan Through November 2011
11. Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test